Related Experiment Video
Updated: Jun 8, 2026
06:03
Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis
Published on: May 9, 2025
Oxaliplatin-induced lung fibrosis.
Arpan Shah1, Zarir F Udwadia, Sachin Almel
1Departments of Chest Medicine, P.D. Hinduja Hospital, Veer Savarkar Marg, Mahim (W), Mumbai, India.
Summary
Oxaliplatin is approved for colorectal cancer but can rarely cause pulmonary fibrosis. This case highlights a rapid progression of this serious lung condition following treatment.
Area of Science:
- Oncology
- Pulmonology
- Pharmacology
Background:
- Oxaliplatin is a US-FDA-approved adjuvant treatment for stage III colorectal carcinoma.
- Most toxicities associated with oxaliplatin are manageable.
- Rare instances of drug-induced pulmonary fibrosis have been documented.
Observation:
- This report details a specific case of a patient experiencing pulmonary fibrosis.
- The pulmonary fibrosis developed rapidly following oxaliplatin treatment.
- This represents an isolated, yet significant, adverse event.
Findings:
- The patient presented with rapidly evolving pulmonary fibrosis.
- The condition was directly linked to oxaliplatin therapy.
- This case underscores a rare but severe adverse effect of the chemotherapy drug.
Implications:
- Clinicians should be vigilant for early signs of pulmonary fibrosis in patients receiving oxaliplatin.
- Further research may be warranted to understand the mechanisms behind oxaliplatin-induced pulmonary fibrosis.
- This case contributes to the literature on rare drug toxicities in cancer treatment.
